Key facts

Invented name
  • Soliris
  • Soliris
Active Substance
Eculizumab
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0306/2012
PIP number
EMEA-000876-PIP02-11-M01
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of Shiga-toxin-producing Escherichia coli haemolytic uraemic syndrome
Route(s) of administration
Intravenous use
Contact for public enquiries

Alexion Europe SAS

France
E-mail: pip.enquiries.eu@alxn.com 
Tel. +33 1 47 10 06 06
Fax +33 1 47 10 06 11

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date
Compliance procedure number
EMEA-000876-PIP01-10-M01
Compliance opinion date
Compliance outcome
Positive

Decision

P/0306/2012: EMA decision of 21 December 2012 on the acceptance of a modification of an agreed paediatric investigation plan for eculizumab (Soliris) (EMEA-000876-PIP02-11-M01)

How useful do you find this page?